交易 Kymera Therapeutics Inc - KYMR 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.41
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.02237 %(-$1.12)使用杠杆的交易規模（大約值）$5,000.00來自杠杆的資金 - 美元（大約值）$4,000.00前往平台: -0.02237%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用0.00015 %($0.01)使用杠杆的交易規模（大約值）$5,000.00來自杠杆的資金 - 美元（大約值）$4,000.00前往平台: 0.00015%
• 隔夜倉息調整時間: 22:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 20.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.02237 %
  (-$1.12)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: 0.00015 %
  ($0.01)

主要統計數據

• 前收盤價: N/A
• 開倉: 131.95
• 1 年變化: 193.88%
• 日區間: 124.5 - 131.95

交易 Kymera Therapeutics Inc - KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body''s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.